Literature DB >> 17047432

[Clinical factors that predicts successful eradication of Helicobacter pylori].

Young Hye Byun1, Yun Ju Jo, Seong Cheol Kim, Jun Seok Lee, Won Yong Shin, Young Sook Park, Seong Hwan Kim, Han Hyo Lee, Moon Hee Song.   

Abstract

BACKGROUND/AIMS: Antibiotic resistance and compliance are regarded to be important which affect the eradication of Helicobacter pylori (H. pylori). However, it is not easy to apply the antibiotic resistance test in clinical field. We investigated other clinical factors predicting the successful eradication of H. pylori.
METHODS: From January 2004 to March 2005, 195 patients with documented H. pylori infection received proton pump inhibitor (PPI)-based triple therapy for one week and were assessed for the underlying chronic illnesses, smoking, alcohol habit, therapeutic indication and compliance.
RESULTS: The intention-to-treat (ITT) eradication rates were 69.2%, while per protocol (PP) analysis with 169 patients showed an initial eradication rate of 79.9%. The eradication rates of H. pylori according to the underlying disease were 73.9% (17/23) in diabetes, 66.7% (18/27) in hypertension, 66.7% (2/3) in renal disease, 100% (9/9) in liver disease, 63.7% (7/11) in cardiovascular disease and 64.3% (9/14) in chronic NSAIDs user. There was no statistical difference in the eradication rates according to the therapeutic indication, underlying disease, sex, age, smoking, alcohol, and PPI. However, the eradication rate was statistically lower in patients with multiple underlying diseases. Eradication rate was significantly higher in patients with good compliance than in those with poor compliance in taking medications (p<0.05).
CONCLUSIONS: Underlying chronic disease does not affect the H. pylori eradication rate significantly. In clinical practice, apart from antibiotic resistance test, drug compliance is the most important factor affecting the H. pylori eradication rate.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17047432

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  4 in total

1.  Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change?

Authors:  Eun Jeong Gong; Sung-Cheol Yun; Hwoon-Yong Jung; Hyun Lim; Kwi-Sook Choi; Ji Yong Ahn; Jeong Hoon Lee; Do Hoon Kim; Kee Don Choi; Ho June Song; Gin Hyug Lee; Jin-Ho Kim
Journal:  J Korean Med Sci       Date:  2014-04-25       Impact factor: 2.153

2.  Triple therapy versus sequential therapy for the first-line Helicobacter pylori eradication.

Authors:  Ji Young Chang; Ki-Nam Shim; Chung Hyun Tae; Ko Eun Lee; Jihyun Lee; Kang Hoon Lee; Chang Mo Moon; Seong-Eun Kim; Hye-Kyung Jung; Sung-Ae Jung
Journal:  BMC Gastroenterol       Date:  2017-01-21       Impact factor: 3.067

3.  Helicobacter pylori eradication in patients with type 2 diabetes mellitus: Multicenter prospective observational study.

Authors:  Seung-Joo Nam; Sung Chul Park; Sang Hoon Lee; Dong Wook Choi; Sung Joon Lee; Chang Seok Bang; Gwang Ho Baik; Jong Kyu Park
Journal:  SAGE Open Med       Date:  2019-02-19

4.  Factors Affecting the Intraluminal Therapy for Helicobacter pylori Infection.

Authors:  Cheng-Yu Ho; Ting-Wen Liu; Yang-Sheng Lin; Yen-Po Chen; Ming-Jen Chen; Horng-Yuan Wang; Tai-Cherng Liou
Journal:  Microorganisms       Date:  2022-02-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.